MCID: CNT005
MIFTS: 52

Central Nervous System Lymphoma

Categories: Cancer diseases, Immune diseases, Neuronal diseases, Rare diseases, Blood diseases

Aliases & Classifications for Central Nervous System Lymphoma

MalaCards integrated aliases for Central Nervous System Lymphoma:

Name: Central Nervous System Lymphoma 12 14
Primary Central Nervous System Lymphoma 69
Primary Cns Lymphoma 12
Cns Lymphoma 69
Microglioma 12

Classifications:



External Ids:

Disease Ontology 12 DOID:3234
ICD9CM 35 200.5
NCIt 47 C9301

Summaries for Central Nervous System Lymphoma

Disease Ontology : 12 A hematologic cancer that has material basis in lymphoma located in central nervous system.

MalaCards based summary : Central Nervous System Lymphoma, also known as primary central nervous system lymphoma, is related to retinal detachment and primary central nervous system lymphoma. An important gene associated with Central Nervous System Lymphoma is MYD88 (Myeloid Differentiation Primary Response 88), and among its related pathways/superpathways are NF-KappaB Family Pathway and Direct p53 effectors. The drugs Methotrexate and Asparaginase have been mentioned in the context of this disorder. Affiliated tissues include brain, b cells and t cells, and related phenotypes are Increased shRNA abundance (Z-score > 2) and hematopoietic system

Related Diseases for Central Nervous System Lymphoma

Diseases in the Central Nervous System Lymphoma family:

Primary Central Nervous System Lymphoma

Diseases related to Central Nervous System Lymphoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 158)
id Related Disease Score Top Affiliating Genes
1 retinal detachment 30.2 CDKN2A TP53
2 primary central nervous system lymphoma 12.6
3 intraocular lymphoma 11.3
4 lymphoma 11.1
5 aids - neurological complications 10.9
6 primary cutaneous cd4+ small/medium-sized pleomorphic t-cell lymphoma 10.7 CDKN2A MYD88
7 anca-associated vasculitis 10.7 CDKN2A MGMT
8 penile disease 10.6 BCL6 CDKN2A
9 deafness, autosomal recessive 22 10.6 CDKN2A IL10
10 graft-versus-host disease, protection against 10.6 IL10 IL2
11 cervical adenoid cystic carcinoma 10.6 CDKN2A TP53
12 split hand split foot nystagmus 10.6 CDKN2A TP53
13 leiomyoma cutis 10.5 CDKN2A TP53
14 anal squamous cell carcinoma 10.5 CDKN2A TP53
15 louse-borne relapsing fever 10.5 CDKN2A IL2
16 plummer vinson syndrome 10.5 BCL6 CDKN2A
17 breast myoepitheliosis 10.5 CDKN2A TP53
18 ritter's disease 10.5 CDKN2A TP53
19 coccidiosis 10.5 CDKN2A TP53
20 adenocarcinoma in situ 10.5 CDKN2A TP53
21 duodenum cancer 10.5 CDKN2A TP53
22 penis paget's disease 10.5 CDKN2A TP53
23 larynx carcinoma in situ 10.5 CDKN2A TP53
24 childhood spinal cord tumor 10.5 BCL6 TP53
25 plantar wart 10.5 IL10 IL2
26 phalanx chondroma 10.5 CDKN2A TP53
27 ischemic optic neuropathy 10.5 BCL6 CXCL12 IL10
28 olfactory neural tumor 10.5 CDKN2A TP53
29 pediatric cns embryonal cell carcinoma 10.5 CDKN2A MGMT
30 orbital lymphoma 10.5 CDKN2A TP53
31 schwannoma of jugular foramen 10.4 MGMT TP53
32 metabolic acidosis 10.4 CXCL12 MYD88
33 non-suppurative otitis media 10.4 CDKN2A TP53
34 barbiturate dependence 10.4 CDKN2A IL2
35 pancreatic agenesis 10.4 CDKN2A TP53
36 heart sarcoma 10.3 CXCL12 IL10 IL2
37 malignant spindle cell melanoma 10.3 IL10 MGMT TP53
38 rectum squamous cell carcinoma 10.3 CDKN2A MGMT TP53
39 myopia 25, autosomal dominant 10.3 IL10 IL2
40 thrombocytopenia 10.3 BCL6 FOXP1 MYD88
41 secondary pulmonary hemosiderosis 10.3 CDKN2A TP53
42 uterine corpus epithelioid leiomyosarcoma 10.3 CXCL12 IL10 IL2
43 cystic lymphangioma 10.3 CDKN2A MGMT TP53
44 dubin-johnson syndrome 10.3 CDKN2A MGMT TP53
45 spinal cord glioma 10.3 CDKN2A MGMT TP53
46 acute porphyria 10.3 CDKN2A MGMT TP53
47 megakaryocytic leukemia 10.3 BCL6 CDKN2A TP53
48 apocrine adenoma 10.2 CDKN2A MGMT TP53
49 pseudotyphus of california 10.2 BCL6 MALT1
50 adult astrocytic tumour 10.2 CDKN2A MGMT TP53

Graphical network of the top 20 diseases related to Central Nervous System Lymphoma:



Diseases related to Central Nervous System Lymphoma

Symptoms & Phenotypes for Central Nervous System Lymphoma

GenomeRNAi Phenotypes related to Central Nervous System Lymphoma according to GeneCards Suite gene sharing:

26
id Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Increased shRNA abundance (Z-score > 2) GR00366-A-118 10 PRDM1
2 Increased shRNA abundance (Z-score > 2) GR00366-A-12 10 MGMT PRDM1 TP53
3 Increased shRNA abundance (Z-score > 2) GR00366-A-120 10 TP53 PRDM1
4 Increased shRNA abundance (Z-score > 2) GR00366-A-132 10 TP53
5 Increased shRNA abundance (Z-score > 2) GR00366-A-149 10 PRDM1
6 Increased shRNA abundance (Z-score > 2) GR00366-A-152 10 PRDM1
7 Increased shRNA abundance (Z-score > 2) GR00366-A-169 10 TP53
8 Increased shRNA abundance (Z-score > 2) GR00366-A-19 10 PRDM1 TP53
9 Increased shRNA abundance (Z-score > 2) GR00366-A-190 10 TP53
10 Increased shRNA abundance (Z-score > 2) GR00366-A-210 10 MGMT
11 Increased shRNA abundance (Z-score > 2) GR00366-A-30 10 PRDM1
12 Increased shRNA abundance (Z-score > 2) GR00366-A-35 10 TP53
13 Increased shRNA abundance (Z-score > 2) GR00366-A-37 10 MGMT
14 Increased shRNA abundance (Z-score > 2) GR00366-A-39 10 TP53
15 Increased shRNA abundance (Z-score > 2) GR00366-A-5 10 MGMT
16 Increased shRNA abundance (Z-score > 2) GR00366-A-8 10 PRDM1
17 Increased shRNA abundance (Z-score > 2) GR00366-A-92 10 MGMT
18 Increased shRNA abundance (Z-score > 2) GR00366-A-99 10 PRDM1
19 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-1 9.7 CDKN2A IL10 IL2 MALT1 MYD88 TP53
20 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-2 9.7 IL10 IL2 MALT1 MYD88 TP53 CDKN2A

MGI Mouse Phenotypes related to Central Nervous System Lymphoma:

44 (show all 11)
id Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 10.11 BCL6 CDKN2A CXCL12 IL10 IL2 MALT1
2 cardiovascular system MP:0005385 10.1 PRDM1 TP53 BCL6 CDKN2A CXCL12 IL10
3 immune system MP:0005387 10.09 BCL6 CDKN2A CXCL12 IL10 IL2 MALT1
4 endocrine/exocrine gland MP:0005379 10.08 MGMT MYD88 PRDM1 TP53 BCL6 CDKN2A
5 mortality/aging MP:0010768 10.07 BCL6 CDKN2A CXCL12 IL10 IL2 MGMT
6 liver/biliary system MP:0005370 9.95 BCL6 CDKN2A CXCL12 IL10 IL2 PRDM1
7 no phenotypic analysis MP:0003012 9.81 BCL6 CDKN2A CXCL12 IL10 IL2 MGMT
8 muscle MP:0005369 9.8 BCL6 CDKN2A CXCL12 IL10 PRDM1 TP53
9 neoplasm MP:0002006 9.8 MYD88 PRDM1 TP53 CDKN2A IL10 IL2
10 reproductive system MP:0005389 9.56 BCL6 CDKN2A CXCL12 IL10 IL2 MYD88
11 respiratory system MP:0005388 9.17 BCL6 CDKN2A IL10 IL2 MGMT MYD88

Drugs & Therapeutics for Central Nervous System Lymphoma

Drugs for Central Nervous System Lymphoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 315)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Methotrexate Approved Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1 1959-05-2, 59-05-2 126941
2
Asparaginase Approved Phase 4,Phase 3,Phase 2 9015-68-3
3
Cyclophosphamide Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 50-18-0, 6055-19-2 2907
4
Cytarabine Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1 147-94-4 6253
5
Daunorubicin Approved Phase 4,Phase 3,Phase 2 20830-81-3 30323
6
Dexamethasone Approved, Investigational, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1 50-02-2 5743
7
Etoposide Approved Phase 4,Phase 3,Phase 2,Phase 1 33419-42-0 36462
8
Methylprednisolone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 83-43-2 6741
9
Prednisolone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 50-24-8 5755
10
Vincristine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 2068-78-2, 57-22-7 5978
11
Ifosfamide Approved Phase 4,Phase 3,Phase 2,Phase 1 3778-73-2 3690
12
rituximab Approved Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1 174722-31-7 10201696
13
Prednisone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 53-03-2 5865
14
Cladribine Approved, Investigational Phase 4 4291-63-8 20279
15
Doxorubicin Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 23214-92-8 31703
16
Thioguanine Approved Phase 4 154-42-7 2723601
17
Vindesine Approved Phase 4,Phase 3,Phase 2 59917-39-4, 53643-48-4 40839
18
Hydrocortisone Approved, Vet_approved Phase 4,Phase 3,Phase 2 50-23-7 5754 657311
19
Teniposide Approved Phase 4,Phase 2 29767-20-2 34698
20
Folic Acid Approved, Nutraceutical, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1 59-30-3 6037
21
leucovorin Approved, Nutraceutical Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1 58-05-9 143 6006
22
Doxil Approved June 1999 Phase 4,Phase 3,Phase 2,Phase 1 31703
23
Fotemustine Experimental Phase 4
24 Antimetabolites Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
25 Antimetabolites, Antineoplastic Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
26 Antirheumatic Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
27 Dermatologic Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
28 Folic Acid Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
29 Immunosuppressive Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
30 Nucleic Acid Synthesis Inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
31 Vitamin B Complex Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
32 Alkylating Agents Phase 4,Phase 3,Phase 2,Phase 1
33 Anti-Bacterial Agents Phase 4,Phase 3,Phase 2,Phase 1
34 Antibiotics, Antitubercular Phase 4,Phase 3,Phase 2,Phase 1
35 Antiemetics Phase 4,Phase 2,Phase 3,Phase 1
36 Anti-Infective Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
37 Anti-Inflammatory Agents Phase 4,Phase 2,Phase 3,Phase 1
38 Antimitotic Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
39 Antineoplastic Agents, Hormonal Phase 4,Phase 2,Phase 3,Phase 1
40 Antineoplastic Agents, Phytogenic Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
41 Antiviral Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
42 Autonomic Agents Phase 4,Phase 2,Phase 3,Phase 1
43 BB 1101 Phase 4,Phase 2,Phase 3,Phase 1
44 Dexamethasone acetate Phase 4,Phase 2,Phase 3,Phase 1 1177-87-3
45 Etoposide phosphate Phase 4,Phase 3,Phase 2,Phase 1
46 Gastrointestinal Agents Phase 4,Phase 2,Phase 3,Phase 1
47 glucocorticoids Phase 4,Phase 2,Phase 3,Phase 1
48 Hormone Antagonists Phase 4,Phase 2,Phase 3,Phase 1
49 Hormones Phase 4,Phase 2,Phase 3,Phase 1
50 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 2,Phase 3,Phase 1

Interventional clinical trials:

(show top 50) (show all 263)

id Name Status NCT ID Phase Drugs
1 Whole Brain Irradiation in Primary Central Nervous System (CNS) Lymphoma (PCNSL) Completed NCT00153530 Phase 4 methotrexate
2 German Multicenter Trial for the Treatment of Newly Diagnosed T-lymphoblastic Lymphoma in Adults Completed NCT00199017 Phase 4 Dexamethasone/Prednisolone;Cyclophosphamide;Vincristine;Daunorubicin;Asparaginase;G-CSF;Mercaptopurine;Cytarabine;Methotrexate;VP16;Vindesine;Adriamycin;Thioguanine;HDARAC;Cladribine
3 Trial for the Treatment of Newly Diagnosed Mature B-Cell Acute Lymphoblastic Leukemia (B-ALL), Burkitt's Non-Hodgkin's Lymphoma (NHL) and Other High-grade Lymphoma in Adults Completed NCT00199082 Phase 4 Adriamycin;Cyclophosphamide;Cytarabine;Dexamethasone/Prednisolone;VP16;Ifosfamide;Methotrexate;G-CSF;Rituximab;Vincristine/Vindesine
4 LINFOTARGAM: Treatment With Chemotherapy Plus Rituximab and Highly Active Antiretroviral Therapy in Patients With Diffuse Large B Cell Lymphoma and Infection With the Human Immunodeficiency Virus (HIV) Completed NCT00466258 Phase 4 R-CHOP;Highly active antiretroviral therapy;Central nervous system (CNS) prophylaxis;Prophylaxis of opportunistic infections and support treatment
5 Treatment of Primary CNS Lymphoma Recruiting NCT01960192 Phase 4 HD-MTX-Ara-C regimen;FVD regimen
6 Treatment of Acute Lymphoblastic Leukemia or Aggressive Lymphoma With Relapse in Central Nervous System With Depocyt Unknown status NCT00199108 Phase 2, Phase 3 Depocyt;Dexamethasone
7 Levofloxacin Compared With Cefepime in Treating Cancer Patients With Fever and Neutropenia Unknown status NCT00020865 Phase 3 cefepime hydrochloride;levofloxacin
8 Ketamine Hydrochloride and Best Pain Management in Treating Cancer Patients With Neuropathic Pain Unknown status NCT01316744 Phase 3 ketamine hydrochloride
9 Early Hospital Discharge or Standard Inpatient Care in Cancer Patients Receiving Antibiotics for Febrile Neutropenia Unknown status NCT00445497 Phase 3 amoxicillin-clavulanate potassium;ciprofloxacin
10 Dalteparin to Prevent Complications in Cancer Patients Receiving Chemotherapy Through a Catheter Completed NCT00006083 Phase 3 Fragmin
11 Personalized Information or Basic Information in Helping Patients Make Decisions About Participating in a Clinical Trial Completed NCT00750009 Phase 3
12 Ondansetron in Treating Patients With Advanced Cancer and Chronic Nausea and Vomiting Not Caused by Cancer Treatment Completed NCT00006348 Phase 3 ondansetron
13 St. John's Wort in Relieving Fatigue in Patients Undergoing Chemotherapy or Hormone Therapy for Cancer Completed NCT00005805 Phase 3
14 Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain Completed NCT00538850 Phase 3 Fentanyl sublingual spray;Placebo
15 Caspofungin Acetate Compared With Amphotericin B Liposomal in Treating Patients With Persistent Fever and Neutropenia Following Cancer Treatment Completed NCT00008359 Phase 3 caspofungin acetate;liposomal amphotericin B
16 Treatment for Chronic Pain in Patients With Advanced Cancer Completed NCT00003687 Phase 3 dextromethorphan hydrobromide;morphine sulfate
17 Levofloxacin to Prevent Infection Following Chemotherapy in Treating Patients With Solid Tumors or Lymphoma Completed NCT00005590 Phase 3 levofloxacin
18 Therapeutic Effects of R-IDARAM and Intrathecal Immunochemotherapy on Elderly Patients With PCNSL Recruiting NCT02836158 Phase 2, Phase 3 R-IDARAM plus intrathecal chemotherapy
19 Maintenance Treatment Versus Observation in Elderly Patients With PCNS Lymphoma Recruiting NCT02313389 Phase 3 Rituximab, Methotrexate, Temozolomide
20 High-dose Chemotherapy and ASCT or Consolidating Conventional Chemotherapy in Primary CNS Lymphoma Recruiting NCT02531841 Phase 3 Arm A (Fortecortin®-ETOPOPHOS®-IFO-cell®-CARBO-cell®);Arm B (TEPADINA®-CARMUBRIS®-Busilvex®)
21 CNS Prophylaxis in Diffuse Large B-cell Lymphoma Recruiting NCT02777736 Phase 3 Methotrexate
22 Optimization of Therapy in Adult Patients With Newly Diagnosed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma by Individualised, Targeted and Intensified Treatment Recruiting NCT02881086 Phase 3 Rituximab;Nelarabine;PEG-Asparaginase;Imatinib;Idarubicin;Dexamethasone;Cyclophosphamide;Fludarabine;Vincristine;Mercaptopurine;VP16;Daunorubicin (DNR);Methotrexate;Cytarabine;Vindesine;Adriamycin;Prednisolone
23 Alectinib Versus Pemetrexed or Docetaxel in Anaplastic Lymphoma Kinase (ALK)-Positive Advanced Non-Small Cell Lung Cancer (NSCLC) Participants Previously Treated With Platinum-Based Chemotherapy and Crizotinib Active, not recruiting NCT02604342 Phase 3 Alectinib;Docetaxel;Pemetrexed
24 A Study Comparing Alectinib With Crizotinib in Treatment-Naive Anaplastic Lymphoma Kinase-Positive Advanced Non-Small Cell Lung Cancer Participants Active, not recruiting NCT02075840 Phase 3 Alectinib;Crizotinib
25 Treatment of PCNSL With R-IDARAM and Intrathecal Immunochemotherapy Enrolling by invitation NCT02657785 Phase 2, Phase 3 R-IDARAM plus intrathecal chemotherapy
26 High-dose Intravenous Methotrexate Versus Intrathecal Methotrexate for Central Nervous System Prophylaxis in DLBCL Not yet recruiting NCT03123718 Phase 3 Intrathecal methotrexate;High-dose intravenous methotrexate
27 Liposomal Cytarabine for Central Nervous System (CNS)-Treatment in High-risk Acute Lymphoblastic Leukemia (ALL) Suspended NCT00991744 Phase 3 Liposomal cytarabine;Intrathecal triple
28 a Phase II Study in Primary Central Nervous System Lymphoma Unknown status NCT00455286 Phase 2 Methotrexate;Methylprednisolone;Temozolomide
29 Chemotherapy and Radiation Therapy in Treating Patients With HIV-Related Primary Central Nervous System Lymphoma Unknown status NCT00003261 Phase 2 methotrexate;zidovudine
30 Temsirolimus in Recurrent Primary Central Nervous System (CNS) Lymphoma Unknown status NCT00942747 Phase 2 temsirolimus
31 Vaccine Therapy and GM-CSF in Treating Patients With CNS Lymphoma Unknown status NCT00621036 Phase 2 methotrexate;thiotepa
32 Pemetrexed and Temozolomide in Treating Patients With Relapsed Primary Central Nervous System Lymphoma (PCNSL) Unknown status NCT01985451 Phase 2 Pemetrexe;Temozolomide
33 Methotrexate and Temozolomide Versus Methotrexate, Procarbazine, Vincristine and Cytarabine Unknown status NCT00503594 Phase 2 Methotrexate and temozolomide;Methotrexate , procarbazine ,vincristine ,cytarabine
34 Temozolomide, Nedaplatin, Vincristine, and Radiotherapy as First-line Treatment in Newly Diagnosed Primary CNS Lymphoma Unknown status NCT01735747 Phase 2 nedaplatin;vincristine;Temozolomide
35 Methotrexate-based Chemo-immunotherapy Followed by Maintenance Therapy for Patients > 65 Years With Central Nervous System (CNS)-Lymphoma Unknown status NCT00989352 Phase 2 Methotrexate;Lomustine;Procarbazine;Rituximab
36 High-Dose Sequential Chemoimmunotherapy for B-Cell Lymphomas With Central Nervous System Involvement Unknown status NCT00801216 Phase 2 High-dose sequential chemotherapy and autologous transplant
37 High-dose Chemotherapy and Stem Cell Transplantation for Central Nervous System (CNS) Relapse of Aggressive Lymphomas Unknown status NCT01148173 Phase 2 Combined systemic and intrathecal chemotherapy followed by HD-ASCT
38 Freiburg ZNS-NHL Study Unknown status NCT00647049 Phase 2 methotrexate;Rituximab;Cytarabine;Thiotepa;Carmustin
39 Safety and Efficacy of an Adult Acute Lymphoblastic Leukemia Chemotherapy for Adult Lymphoblastic Lymphoma Unknown status NCT00195871 Phase 2 Prednisone, vincristine, daunorubicin , cyclophosphamide , L.-asparaginase, cytosine-arabinoside, methotrexate, etoposide
40 Combination Chemotherapy Plus Filgrastim in Treating Patients With HIV-Related Non-Hodgkin's Lymphoma Unknown status NCT00032149 Phase 1, Phase 2 cyclophosphamide;etoposide;mitoxantrone hydrochloride;prednisolone;vincristine sulfate
41 Phenylbutyrate and Valganciclovir in Treating Patients With Relapsed or Refractory Epstein-Barr Virus-Positive Cancer Unknown status NCT00387530 Phase 2 oral sodium phenylbutyrate;valganciclovir
42 Phase II Study to Evaluate the Combination of Rituximab and DepoCyte® in the C5R Chemotherapy Protocol in Patients Between the Ages of 18 and 60 Years With Primary Cerebral Non-Hodgkin Lymphoma and Systemic Diffuse Large B-cell Lymphoma With Neuromeningea Unknown status NCT00553943 Phase 2 Rituximab, Cytarabine
43 Zidovudine Plus Interleukin-2 and Ganciclovir in Treating Patients With AIDS-Related Primary Central Nervous System Lymphoma Completed NCT00006264 Phase 2 ganciclovir;zidovudine
44 Trial for Patients With Newly Diagnosed Primary Central Nervous System (CNS) Lymphoma Completed NCT01011920 Phase 2 Methotrexate;Ara-C;Rituximab;Thiotepa;BCNU
45 Buparlisib (BKM120) In Patients With Recurrent/Refractory Primary Central Nervous System Lymphoma (PCNSL) and Recurrent/Refractory Secondary Central Nervous System Lymphoma (SCNSL) Completed NCT02301364 Phase 2 Buparlisib (BKM120)
46 Idarubicin Based Combined Modality Therapy in Primary CNS Lymphoma Completed NCT00193973 Phase 2 Idarubicin, Methotrexate, Filgrastim, intrathecal Ara-C
47 Combination Chemotherapy, Monoclonal Antibody, and Radiation Therapy in Treating Patients With Primary Central Nervous System Lymphoma Completed NCT00068250 Phase 1, Phase 2 methotrexate;temozolomide
48 Phase II Trial of Combined Modality Treatment in Primary Central Nervous System Lymphoma Completed NCT00210314 Phase 2 high dose methotrexate;high dose cytarabine
49 Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Newly Diagnosed Central Nervous System Lymphoma Completed NCT00003632 Phase 2 carmustine;cytarabine;etoposide;melphalan;methotrexate
50 Phase II Trial of Sequential Chemotherapy and Radiotherapy for AIDS-Related Primary Central Nervous System Lymphoma Completed NCT00000801 Phase 2 Filgrastim;Vincristine sulfate;Doxorubicin hydrochloride;Cyclophosphamide;Cytarabine;Dexamethasone

Search NIH Clinical Center for Central Nervous System Lymphoma

Genetic Tests for Central Nervous System Lymphoma

Anatomical Context for Central Nervous System Lymphoma

MalaCards organs/tissues related to Central Nervous System Lymphoma:

39
Brain, B Cells, T Cells, Liver, Lung, Bone, Bone Marrow

Publications for Central Nervous System Lymphoma

Articles related to Central Nervous System Lymphoma:

(show top 50) (show all 674)
id Title Authors Year
1
Current management of primary central nervous system lymphoma. ( 28841800 )
2017
2
Genome-wide DNA methylation profiling identifies primary central nervous system lymphoma as a distinct entity different from systemic diffuse large B-cell lymphoma. ( 28058506 )
2017
3
Soluble TACI and soluble BCMA as biomarkers in primary central nervous system lymphoma. ( 28521029 )
2017
4
High-dose chemotherapy with thiotepa, busulfan, and cyclophosphamide and autologous stem cell transplantation for pediatric primary central nervous system lymphoma in first complete remission. ( 28542721 )
2017
5
Incidence and outcomes of primary central nervous system lymphoma in solid organ transplant recipients. ( 28805292 )
2017
6
Patterns of relapse in primary central nervous system lymphoma: inferences regarding the role of the neuro-vascular unit and monoclonal antibodies in treating occult CNS disease. ( 28577579 )
2017
7
Promoter methylation attenuates SHP1 expression and function in patients with primary central nervous system lymphoma. ( 27959415 )
2017
8
Treatment with methotrexate, rituximab, and cytosine arabinoside followed by autologous stem cell transplantation in primary central nervous system lymphoma: A single-center experience. ( 28633037 )
2017
9
Quantitative Evaluation of Diffusion and Dynamic Contrast-Enhanced Magnetic Resonance Imaging for Differentiation Between Primary Central Nervous System Lymphoma and Glioblastoma. ( 28806317 )
2017
10
Non-invasive detection of somatic mutations using next-generation sequencing in primary central nervous system lymphoma. ( 28636991 )
2017
11
Advances in the management of primary central nervous system lymphoma. ( 28949937 )
2017
12
Advances in Pathobiology of Primary Central Nervous System Lymphoma. ( 28776551 )
2017
13
Comparison between Glioblastoma and Primary Central Nervous System Lymphoma Using MR Image-based Texture Analysis. ( 28638001 )
2017
14
Utility of post-therapy brain surveillance imaging in the detection of primary central nervous system lymphoma relapse. ( 28012348 )
2017
15
Population-based experience on primary central nervous system lymphoma 2000-2012: the incidence is increasing. ( 28084866 )
2017
16
Monocyte chemoattractant protein 1 expression and proliferation in primary central nervous system lymphoma. ( 28693163 )
2017
17
Effect of rituximab on primary central nervous system lymphoma: a meta-analysis. ( 28900847 )
2017
18
Role of radiation therapy in primary central nervous system lymphoma : KROG 14-20 Collaborative Study of Brain and Lymphoma Committee. ( 28939931 )
2017
19
Primary central nervous system lymphoma: time for diagnostic biomarkers and biotherapies? ( 28922238 )
2017
20
A Comprehensive Assessment of Toxicities in Patients with Central Nervous System Lymphoma Undergoing Autologous Stem Cell Transplantation Using Thiotepa, Busulfan, and Cyclophosphamide Conditioning. ( 27713090 )
2017
21
Diagnosis and management of primary central nervous system lymphoma. ( 28950405 )
2017
22
Comparing the Efficacy of DeVIC Therapy and High-dose Methotrexate Monotherapy with Whole-brain Radiation Therapy for Newly-diagnosed Primary Central Nervous System Lymphoma: A Single Institution Study. ( 28870957 )
2017
23
High-dose chemotherapy and autologous stem cell transplantation for primary central nervous system lymphoma: a multi-centre retrospective analysis from the United Kingdom. ( 28581466 )
2017
24
The prognostic role of CD68 and FoxP3 expression in patients with primary central nervous system lymphoma. ( 28508176 )
2017
25
Methotrexate plus idarubicin improves outcome of patients with primary central nervous system lymphoma. ( 28881844 )
2017
26
Interim (18)F-FGD PET/CT may not predict the outcome in primary central nervous system lymphoma patients treated with sequential treatment with methotrexate and cytarabine. ( 28725988 )
2017
27
The role of upfront autologous stem cell transplantation in high-risk younger patients with primary central nervous system lymphoma. ( 27018207 )
2016
28
A Case of Primary Central Nervous System Lymphoma Located at Brain Stem in a Child. ( 27867930 )
2016
29
Recurrent mutations of CD79B and MYD88 are the hallmark of primary central nervous system lymphomas. ( 26111727 )
2016
30
A new prognostic model using absolute lymphocyte count in patients with primary central nervous system lymphoma. ( 26918738 )
2016
31
A Case of Primary Central Nervous System Lymphoma with Ciliary Body Involvement. ( 27174337 )
2016
32
The challenge of adequate imaging surveillance in primary central nervous system lymphoma. ( 28025387 )
2016
33
Clinical Utility of Thallium-201 Single Photon Emission Computed Tomography and Cerebrospinal Fluid Epstein-Barr Virus Detection Using Polymerase Chain Reaction in the Diagnosis of AIDS-Related Primary Central Nervous System Lymphoma. ( 27330874 )
2016
34
Hyperglycemia is associated with poor survival in primary central nervous system lymphoma patients. ( 28058711 )
2016
35
Prognostic Significance of High Ki-67 Index and Histogenetic Subclassification in Primary Central Nervous System Lymphoma. ( 27490760 )
2016
36
Role of rituximab in treatment of patients with primary central nervous system lymphoma: a retrospective analysis of the Czech lymphoma study group registry. ( 27087066 )
2016
37
mTORC1 signaling in primary central nervous system lymphoma. ( 27512609 )
2016
38
Long-term survival in AIDS-related primary central nervous system lymphoma. ( 27576871 )
2016
39
Primary central nervous system lymphoma and atypical glioblastoma: differentiation using the initial area under the curve derived from dynamic contrast-enhanced MR and the apparent diffusion coefficient. ( 27436023 )
2016
40
Involvement of cranial nerves in a patient with secondary central nervous system lymphoma. ( 27208575 )
2016
41
The Challenge of Primary Central Nervous System Lymphoma. ( 27888882 )
2016
42
Utility of dynamic contrast-enhanced magnetic resonance imaging for differentiating glioblastoma, primary central nervous system lymphoma and brain metastatic tumor. ( 27666608 )
2016
43
Can morphological MRI differentiate between primary central nervous system lymphoma and glioblastoma? ( 27894359 )
2016
44
The Influence of Corticosteroids on Diagnostic Accuracy of Biopsy for Primary Central Nervous System Lymphoma. ( 27468790 )
2016
45
Application value of magnetic resonance imaging in diagnosing central nervous system lymphoma. ( 27182246 )
2016
46
Occam's Razor Need Not Apply: A Case of Concurrent Cryptococcal Meningitis and Primary Central Nervous System Lymphoma in an Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome Patient. ( 26835474 )
2016
47
Neuroimaging in Central Nervous System Lymphoma. ( 27443998 )
2016
48
Primary central nervous system lymphoma of T-cell origin: an unusual cause of spinal cord disease. ( 27878765 )
2016
49
Value of pretherapeutic DWI in evaluating prognosis and therapeutic effect in immunocompetent patients with primary central nervous system lymphoma given high-dose methotrexate-based chemotherapy: ADC-based assessment. ( 27341986 )
2016
50
Management of primary central nervous system lymphoma in children. ( 27913505 )
2016

Variations for Central Nervous System Lymphoma

Cosmic variations for Central Nervous System Lymphoma:

9 (show all 34)
id Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA Conf
1 COSM10656 TP53 haematopoietic and lymphoid tissue,central nervous system,lymphoid neoplasm,primary central nervous system lymphoma c.742C>T p.R248W 3
2 COSM43448 TNFAIP3 haematopoietic and lymphoid tissue,central nervous system,lymphoid neoplasm,primary central nervous system lymphoma c.2273C>G p.P758R 3
3 COSM5878666 TET2 haematopoietic and lymphoid tissue,central nervous system,lymphoid neoplasm,primary central nervous system lymphoma c.4034A>C p.Y1345S 3
4 COSM4440710 TBL1XR1 haematopoietic and lymphoid tissue,central nervous system,lymphoid neoplasm,primary central nervous system lymphoma c.70T>C p.S24P 3
5 COSM4440704 TBL1XR1 haematopoietic and lymphoid tissue,central nervous system,lymphoid neoplasm,primary central nervous system lymphoma c.1336T>G p.Y446D 3
6 COSM4440697 TBL1XR1 haematopoietic and lymphoid tissue,central nervous system,lymphoid neoplasm,primary central nervous system lymphoma c.1255T>A p.S419T 3
7 COSM4440708 TBL1XR1 haematopoietic and lymphoid tissue,central nervous system,lymphoid neoplasm,primary central nervous system lymphoma c.458G>A p.G153E 3
8 COSM4440695 TBL1XR1 haematopoietic and lymphoid tissue,central nervous system,lymphoid neoplasm,primary central nervous system lymphoma c.1261G>C p.D421H 3
9 COSM4440707 TBL1XR1 haematopoietic and lymphoid tissue,central nervous system,lymphoid neoplasm,primary central nervous system lymphoma c.596G>A p.S199N 3
10 COSM4440703 TBL1XR1 haematopoietic and lymphoid tissue,central nervous system,lymphoid neoplasm,primary central nervous system lymphoma c.1376G>A p.S459N 3
11 COSM4440696 TBL1XR1 haematopoietic and lymphoid tissue,central nervous system,lymphoid neoplasm,primary central nervous system lymphoma c.1256C>T p.S419F 3
12 COSM4440698 TBL1XR1 haematopoietic and lymphoid tissue,central nervous system,lymphoid neoplasm,primary central nervous system lymphoma c.1335G>T p.V445V 3
13 COSM4440709 TBL1XR1 haematopoietic and lymphoid tissue,central nervous system,lymphoid neoplasm,primary central nervous system lymphoma c.148A>T p.I50F 3
14 COSM4440712 TBL1XR1 haematopoietic and lymphoid tissue,central nervous system,lymphoid neoplasm,primary central nervous system lymphoma c.230C>T p.P77L 3
15 COSM4440706 TBL1XR1 haematopoietic and lymphoid tissue,central nervous system,lymphoid neoplasm,primary central nervous system lymphoma c.637C>A p.H213N 3
16 COSM4440705 TBL1XR1 haematopoietic and lymphoid tissue,central nervous system,lymphoid neoplasm,primary central nervous system lymphoma c.1274G>T p.R425M 3
17 COSM4440713 TBL1XR1 haematopoietic and lymphoid tissue,central nervous system,lymphoid neoplasm,primary central nervous system lymphoma c.229C>A p.P77T 3
18 COSM1716590 STAT5B haematopoietic and lymphoid tissue,central nervous system,lymphoid neoplasm,primary central nervous system lymphoma c.1924A>C p.N642H 3
19 COSM1155745 STAT3 haematopoietic and lymphoid tissue,central nervous system,lymphoid neoplasm,primary central nervous system lymphoma c.1981G>C p.D661H 3
20 COSM97162 PRDM1 haematopoietic and lymphoid tissue,central nervous system,lymphoid neoplasm,primary central nervous system lymphoma c.183G>A p.E62fs 3
21 COSM97163 PRDM1 haematopoietic and lymphoid tissue,central nervous system,lymphoid neoplasm,primary central nervous system lymphoma c.556+1G>C p.? 3
22 COSM85940 MYD88 haematopoietic and lymphoid tissue,central nervous system,lymphoid neoplasm,primary central nervous system lymphoma c.794T>C p.L265P 3
23 COSM517 KRAS haematopoietic and lymphoid tissue,central nervous system,lymphoid neoplasm,primary central nervous system lymphoma c.34G>A p.G12S 3
24 COSM306058 JAK3 haematopoietic and lymphoid tissue,central nervous system,lymphoid neoplasm,primary central nervous system lymphoma c.1533G>T p.M511I 3
25 COSM5878665 DNMT3A haematopoietic and lymphoid tissue,central nervous system,lymphoid neoplasm,primary central nervous system lymphoma c.2207G>T p.R736L 3
26 COSM144393 CD79B haematopoietic and lymphoid tissue,central nervous system,lymphoid neoplasm,primary central nervous system lymphoma c.586T>A p.Y196N 3
27 COSM220733 CD79B haematopoietic and lymphoid tissue,central nervous system,lymphoid neoplasm,primary central nervous system lymphoma c.587A>C p.Y196S 3
28 COSM1737939 CD79B haematopoietic and lymphoid tissue,central nervous system,lymphoid neoplasm,primary central nervous system lymphoma c.586T>G p.Y196D 3
29 COSM220734 CD79B haematopoietic and lymphoid tissue,central nervous system,lymphoid neoplasm,primary central nervous system lymphoma c.586T>C p.Y196H 3
30 COSM220736 CD79B haematopoietic and lymphoid tissue,central nervous system,lymphoid neoplasm,primary central nervous system lymphoma c.587A>G p.Y196C 3
31 COSM5045028 CD79B haematopoietic and lymphoid tissue,central nervous system,lymphoid neoplasm,primary central nervous system lymphoma c.591G>C p.E197D 3
32 COSM43452 CARD11 haematopoietic and lymphoid tissue,central nervous system,lymphoid neoplasm,primary central nervous system lymphoma c.343T>A p.F115I 3
33 COSM43451 CARD11 haematopoietic and lymphoid tissue,central nervous system,lymphoid neoplasm,primary central nervous system lymphoma c.1010G>A p.R337Q 3
34 COSM43455 CARD11 haematopoietic and lymphoid tissue,central nervous system,lymphoid neoplasm,primary central nervous system lymphoma c.343T>C p.F115L 3

Expression for Central Nervous System Lymphoma

Search GEO for disease gene expression data for Central Nervous System Lymphoma.

Pathways for Central Nervous System Lymphoma

GO Terms for Central Nervous System Lymphoma

Cellular components related to Central Nervous System Lymphoma according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 replication fork GO:0005657 8.62 BCL6 TP53

Biological processes related to Central Nervous System Lymphoma according to GeneCards Suite gene sharing:

(show all 17)
id Name GO ID Score Top Affiliating Genes
1 negative regulation of cell proliferation GO:0008285 9.87 BCL6 CDKN2A IL10 TP53
2 negative regulation of cell growth GO:0030308 9.7 BCL6 CDKN2A TP53
3 cobalamin metabolic process GO:0009235 9.56 MTR TCN2
4 positive regulation of gene expression GO:0010628 9.55 PRDM1 TP53
5 negative regulation of cell-matrix adhesion GO:0001953 9.54 BCL6 CDKN2A
6 regulation of inflammatory response GO:0050727 9.54 BCL6 FOXP1 MYD88
7 negative regulation of growth of symbiont in host GO:0044130 9.51 IL10 MYD88
8 positive regulation of interleukin-17 production GO:0032740 9.49 IL2 MYD88
9 response to molecule of bacterial origin GO:0002237 9.48 IL10 MALT1
10 replicative senescence GO:0090399 9.46 CDKN2A TP53
11 positive regulation of histone deacetylation GO:0031065 9.43 BCL6 TP53
12 positive regulation of regulatory T cell differentiation GO:0045591 9.4 BCL6 IL2
13 negative regulation of B cell proliferation GO:0030889 9.33 CDKN2A IL10 PRDM1
14 regulation of tumor necrosis factor production GO:0032680 9.32 FOXP1 MYD88
15 type 2 immune response GO:0042092 9.26 BCL6 IL10
16 negative regulation of apoptotic process GO:0043066 9.17 BCL6 IL10 IL2 MALT1 MGMT MYD88
17 negative regulation of B cell apoptotic process GO:0002903 9.13 BCL6 FOXP1 IL2

Molecular functions related to Central Nervous System Lymphoma according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 growth factor activity GO:0008083 9.43 CXCL12 IL10 IL2
2 cobalamin binding GO:0031419 9.16 MTR TCN2
3 kinase activator activity GO:0019209 8.96 IL2 MALT1
4 protein self-association GO:0043621 8.92 FOXP1 MALT1 MYD88 TP53

Sources for Central Nervous System Lymphoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....